Trial Profile
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate 568
- Sponsors Bristol-Myers Squibb
- 19 Nov 2022 Pooled analysis from CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012) assessing OS, PFS, ORR, DOR, and safety published in the Annals of Oncology
- 29 Aug 2022 Results of pooled analysis form CheckMate 227 Part 1, CheckMate 817 cohort A, CheckMate 568 Part 1 analyzing safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer, published in the Journal of Thoracic Oncology
- 21 Jul 2022 Status changed from active, no longer recruiting to completed.